Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Cerebrospinal fluid biomarker analysis in Alzheimer's disease : a pilot study in Croatia (CROSBI ID 548629)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Malnar, Martina ; Petek Tarnik, Iva ; Košiček, Marko ; Pavelin, Sanda ; Titlić, Marina ; Trkanjec, Zlatko ; Demarin, Vida ; Hećimović, Silva Cerebrospinal fluid biomarker analysis in Alzheimer's disease : a pilot study in Croatia // Paediatria Croatica. Supplement. 2009. str. 69-69

Podaci o odgovornosti

Malnar, Martina ; Petek Tarnik, Iva ; Košiček, Marko ; Pavelin, Sanda ; Titlić, Marina ; Trkanjec, Zlatko ; Demarin, Vida ; Hećimović, Silva

engleski

Cerebrospinal fluid biomarker analysis in Alzheimer's disease : a pilot study in Croatia

Alzheimer's disease (AD) is the leading cause of dementia with no adequate therapies and no tests that would enable accurate diagnosis of AD during lifetime. The aim of this work was to evaluate the levels of Abeta42, total-tau (t-tau), phospho181-tau (P181-tau) in the cerebrospinal fluid (CSF) and/or CSF t-tau/Abeta42 ratio as an early biomarker(s) of Alzheimer's disease. In this pilot study we analyzed CSF samples of clinically assesed AD individuals (N=12, mean age=73 years), healthy age-matched individuals (N=13, mean age=63 years) and demented patients with no certain diagnosis (N=11, mean age= 69 years). The levels of Abeta42, t-tau and P181-tau in CSF were determined using ELISA assay. Our results show that CSF-Abeta42 levels and CSF t-tau/Abeta42 ratio give 75% and 100% specificity of detecting AD cases, respectively, suggesting that the two biomarkers may be used for early and differential diagnosis of Alzheimer's disease. In agreement with previous study by Fagan et al. (2007) we found low CSF-Abeta42 levels ( 476 pg/mL) and high CSF t-tau/Abeta42 ratio ( 0.744) to be characteristic for AD cases. Among 12 clinically diagnosed AD individuals we identified three non-AD cases, while 64% (7/11) of demented individuals with no certain diagnosis were detected to have AD by the CSF analysis. Interestingly, two cases of AD were found in the age-matched control group, indicating that this test may detect non-demented and/or mildly cognitively impaired cases (MCIs) who will develop Alzheimer's disease. In summary, our pilot study supports CSF-Abeta42 and CSF t-tau/Abeta42 levels as early biomarkers of Alzheimer's disease.

Alzheimer's disease; APP protein; Abeta peptide; biomarkers; diagnosis; neurodegeneration; tau

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

69-69.

2009.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Paediatria Croatica. Supplement

1330-724X

Podaci o skupu

Balkan meeting on human genetics (8 ; 2009)

poster

14.05.2009-17.05.2009

Cavtat, Hrvatska

Povezanost rada

Temeljne medicinske znanosti

Indeksiranost